The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Ross Osborn - Cantor Fitzgerald & Co. - Analyst
: Hi, good morning, everyone. So I understand the [special] order centers, but would be curious to hear if the biopharma opportunity still interesting,
maybe the post market studies phase?
Question: Ross Osborn - Cantor Fitzgerald & Co. - Analyst
: Okay, great. And then sticking with Veris, would you provide an update on where you stand in development work on next gen PortIO offerings?
Question: Ross Osborn - Cantor Fitzgerald & Co. - Analyst
: Yes.
Question: Ed Woo - Ascendiant Capital Markets LLC - Analyst
: Thank you for taking my question. My question is on the recently announced the incubator that you guys are developing. What is your exact
responsibility of any financial commitments to -- for the incubator?
Question: Ed Woo - Ascendiant Capital Markets LLC - Analyst
: Great. Well, thank you. Wish you guys. Good luck. Thank you.
Question: Nick Sherwood - Maxim Group LLC - Analyst
: (multiple speakers) Thank you for taking my question. For the incubator, do you plan on being the majority owners of those products that are spun
also the incubator? Are you open to having minority stakes in CarpX or any of the other products?
Question: Nick Sherwood - Maxim Group LLC - Analyst
: Awesome. Thanks for the detail. And then my final question is how far along in the progress for securing independent financing for the Veris system
to clear the path to FDA submission in the five 10-K clearance?
Question: Nick Sherwood - Maxim Group LLC - Analyst
: Can you share with us the size of that target pool of the institutions?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 27, 2024 / 12:30PM, PAVM.OQ - Q4 2023 PAVmed Inc Earnings Call
Question: Nick Sherwood - Maxim Group LLC - Analyst
: Yes, that's perfect. Thank you for answering my questions, and I'll hop back into the queue.
| 
